Key facts
- This page summarizes Jason A. Keyes's Form 4 filing for Sesen Bio, Inc. (CARM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Jun 2022, 18:29.
Jason A. Keyes - 22 Jun 2022 Form 4 Insider Report for Sesen Bio, Inc. (CARM)
- Reporting relationship
- Director
- Issuer ticker
- CARM
- Reported as of
- 22 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jun 2022, 18:29:19 UTC
- Prior SEC filing
- 06 Jun 2022
- Next SEC filing
- 30 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- Mark R. Sullivan, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jason A. Keyes filed Form 4 for Sesen Bio, Inc. (CARM) on 24 Jun 2022.
Change
- Previous filing in this sequence was filed on 06 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CARM
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +40,000
- Change %
- Price
- $0.000000
- Shares after
- 40,000
- Date
- 22 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CARM
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +65,000
- Change %
- Price
- $0.000000
- Shares after
- 65,000
- Date
- 22 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 65,000
- Exercise price
- $0.7900
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted stock units ("RSUs") which shall vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Sesen Bio, Inc. common stock.
Footnote F2
The option was granted on June 22, 2022 and vests over one year, with 1/12th of the shares subject to the option vesting at the end of each successive one-month period following the grant date until the earlier of a) the day that is one business day prior to the date of the next annual meeting and b) the first anniversary of the grant date, at which time such option shall be fully vested.